DOP2013000053A - Sistemas terapéuticos transdérmicos con lámina de protección inhibidora de la cristalización - Google Patents

Sistemas terapéuticos transdérmicos con lámina de protección inhibidora de la cristalización

Info

Publication number
DOP2013000053A
DOP2013000053A DO2013000053A DO2013000053A DOP2013000053A DO P2013000053 A DOP2013000053 A DO P2013000053A DO 2013000053 A DO2013000053 A DO 2013000053A DO 2013000053 A DO2013000053 A DO 2013000053A DO P2013000053 A DOP2013000053 A DO P2013000053A
Authority
DO
Dominican Republic
Prior art keywords
protection sheet
transdermal therapeutic
therapeutic systems
crystallization inhibiting
inhibiting protection
Prior art date
Application number
DO2013000053A
Other languages
English (en)
Spanish (es)
Inventor
Stefan Bracht
Thomas Langguth
Ildiko Terebesi
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000053(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of DOP2013000053A publication Critical patent/DOP2013000053A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2013000053A 2010-09-06 2013-03-06 Sistemas terapéuticos transdérmicos con lámina de protección inhibidora de la cristalización DOP2013000053A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)

Publications (1)

Publication Number Publication Date
DOP2013000053A true DOP2013000053A (es) 2013-07-15

Family

ID=44653285

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000053A DOP2013000053A (es) 2010-09-06 2013-03-06 Sistemas terapéuticos transdérmicos con lámina de protección inhibidora de la cristalización

Country Status (33)

Country Link
US (2) US8557279B2 (enExample)
EP (1) EP2613771A1 (enExample)
JP (2) JP6104800B2 (enExample)
KR (1) KR20130114127A (enExample)
CN (1) CN103079549B (enExample)
AP (1) AP3586A (enExample)
AR (1) AR082907A1 (enExample)
AU (1) AU2011298892B2 (enExample)
BR (1) BR112013005305A2 (enExample)
CA (1) CA2810103C (enExample)
CL (1) CL2013000636A1 (enExample)
CO (1) CO6690753A2 (enExample)
CR (1) CR20130098A (enExample)
CU (1) CU24172B1 (enExample)
DE (1) DE102010040299A1 (enExample)
DO (1) DOP2013000053A (enExample)
EA (1) EA032575B1 (enExample)
EC (1) ECSP13012477A (enExample)
GT (1) GT201300062A (enExample)
IL (2) IL224980A (enExample)
MA (1) MA34581B1 (enExample)
MX (1) MX2013002602A (enExample)
MY (1) MY162768A (enExample)
NZ (1) NZ607630A (enExample)
PE (2) PE20131138A1 (enExample)
PH (1) PH12013500429A1 (enExample)
SG (2) SG10201506927TA (enExample)
TN (1) TN2013000087A1 (enExample)
TW (1) TWI576245B (enExample)
UA (1) UA110217C2 (enExample)
UY (1) UY33590A (enExample)
WO (1) WO2012031985A1 (enExample)
ZA (1) ZA201301389B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (enExample) * 1987-04-02 1990-06-29 Ciba Geigy Ag
DE58909570D1 (de) 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
MX9101787A (es) 1990-10-29 1992-06-05 Alza Corp Formulaciones,metodos y dispositivos anticonceptivos transdermicos
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
NZ518723A (en) 1999-11-24 2004-04-30 Agile Therapeutics Inc Improved transdermal contraceptive delivery system and process
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
AU2002235155A1 (en) 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
ME00147B (me) * 2003-02-21 2010-10-10 Schering Ag Uv-stabilni transdermalni flasteri
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4965263B2 (ja) 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
MX2007004315A (es) * 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
AU2009302853B2 (en) * 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
IL224980A (en) 2017-07-31
PE20180198A1 (es) 2018-01-26
JP2016216500A (ja) 2016-12-22
AU2011298892B2 (en) 2015-03-12
US20140018751A1 (en) 2014-01-16
MY162768A (en) 2017-07-14
JP6104800B2 (ja) 2017-03-29
US20120082714A1 (en) 2012-04-05
TN2013000087A1 (en) 2014-06-25
PE20131138A1 (es) 2013-10-26
AP2013006787A0 (en) 2013-04-30
ZA201301389B (en) 2021-05-26
SG187941A1 (en) 2013-04-30
MX2013002602A (es) 2013-04-08
TW201217165A (en) 2012-05-01
EP2613771A1 (de) 2013-07-17
IL251124B (en) 2020-07-30
UA110217C2 (en) 2015-12-10
CU20130031A7 (es) 2013-05-31
IL251124A0 (en) 2017-04-30
EA032575B1 (ru) 2019-06-28
GT201300062A (es) 2015-01-16
JP2013536828A (ja) 2013-09-26
TWI576245B (zh) 2017-04-01
CO6690753A2 (es) 2013-06-17
WO2012031985A1 (de) 2012-03-15
AU2011298892A1 (en) 2013-03-28
US8557279B2 (en) 2013-10-15
AR082907A1 (es) 2013-01-16
US9060955B2 (en) 2015-06-23
CN103079549B (zh) 2016-11-02
ECSP13012477A (es) 2013-04-30
CR20130098A (es) 2013-05-15
AP3586A (en) 2016-02-10
BR112013005305A2 (pt) 2016-08-16
NZ607630A (en) 2015-02-27
CN103079549A (zh) 2013-05-01
CA2810103A1 (en) 2012-03-15
EA201390246A1 (ru) 2013-09-30
PH12013500429A1 (en) 2019-10-07
KR20130114127A (ko) 2013-10-16
CL2013000636A1 (es) 2013-09-13
CU24172B1 (es) 2016-04-25
UY33590A (es) 2011-10-31
MA34581B1 (fr) 2013-10-02
CA2810103C (en) 2019-06-18
DE102010040299A1 (de) 2012-03-08
SG10201506927TA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
ECSP15014941A (es) Compuestos antivíricos para el vsr
GT200800185A (es) Formulaciones para administracion parenteral de compuestos y sus usos
PA8849701A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico
BR112015002821A8 (pt) compostos inibidores de neprilisina, composição farmacêutica e uso dos compostos
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
BR112015024271A2 (pt) sistema de fornecimento transdérmico
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
MX390536B (es) Composicion farmaceutica topica que comprende al menos amitriptilina para el tratamiento del dolor neuropatico periferico.
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
BR112017013255A2 (pt) emplastro em gel
TR201010683A1 (tr) Vildagliptin formülasyonları.
ES2614481T3 (es) Composición para la administración de principios activos mediante dispositivos de implante
ECSP13012477A (es) Sistemas terapéuticos transdérmicos con lámina de protección (release liner) inhibidora de la cristalización
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
MX2014008693A (es) Administracion transdermica de hormonas.
ECSP12012332A (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
CL2012003661A1 (es) Composición farmacéutica de liberación sostenida que comprende un compuesto derivado de 2-feniltiazol; y uso en el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal.
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
BR112016006485A2 (pt) composições de liberação pulsátil revestidas por compressão
BR112012009243A2 (pt) composto com eluição de medicamentos
TR201714149A2 (tr) Ulipristal asetat içeren bir tablet formülasyonu.
CO6630144A2 (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso